Zhaoke Ophthalmology Limited

6622

KYG989M51017

Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company's products include innovative drugs and generic drugs. The Company 's products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.442 CNY

Average target price

7.158 CNY

Spread / Average Target

+396.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHAOKE OPHTHALMOLOGY LIMITED	-60.76%	109M
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.54%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.55%	211B
NOVARTIS AG	-0.75%	203B
ROCHE HOLDING AG	-10.31%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 03:57:54 2024-04-19 am EDT			5-day change	1st Jan Change
1.55 ^HKD	-0.64%		-0.64%	-60.76%

Apr. 08	Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	CI
Mar. 27	Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	Apr. 08	CI
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea	Jan. 29	MT
Zhaoke Ophthalmology's Investigational New Drug Applications for Pupil-Modulating Eye Drops Given Green Light by Chinese Regulator	Jan. 24	MT
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia	Jan. 24	CI
Zhaoke Ophthalmology Limited Announces Executive Changes	Nov. 27	CI
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan	Nov. 14	MT
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study	23-10-12	MT
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China	23-10-12	CI
Zhaoke Ophthalmology Enlists Patients for 2 Drug Trials; Will Refile NDA for Eye Gel	23-10-03	MT
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel	23-10-03	CI
Zhaoke Ophthalmology's Loss Widens in H1	23-08-24	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Zhaoke Ophthalmology Concludes Phase III Trial of Myopia Medication	23-08-10	MT
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial	23-08-09	CI
Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer for the Treatment of Dry Eye Disease	23-06-08	CI
US FDA Approves New Drug Application of Zhaoke Ophthalmology's Eye Drops for Nearsightedness; Shares Surge 12%	23-06-06	MT
Zhaoke Ophthalmology Partner Achieves Positive Top-Line Results from Eye Drop's Phase 3 Trial	23-04-26	MT
Zhaoke Ophthalmology Loss Narrows in 2022	23-03-27	MT
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea	23-03-27	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Zhaoke Ophthalmology Limited Enters into Distribution Agreement with Kwangdong Pharmaceutical to Commercialize NVK002 in South Korea	23-03-26	CI
Lee’s Pharmaceutical Holdings Warns of Plunge in 2022 Profit	23-03-21	MT
Zhaoke Ophthalmology Gets Nod for Marketing of Eye Drop	23-02-21	MT
Zhaoke Ophthalmology Limited Obtains Marketing Authorization for Bimatoprost Timolol Eye Drop from the National Medical Products Administration	23-02-20	CI

Zhaoke Ophthalmology Limited

Equities